<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148512" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Taxane Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ismail</surname>
            <given-names>Uzma</given-names>
          </name>
          <aff>Specialist Care Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Killeen</surname>
            <given-names>Robert B.</given-names>
          </name>
          <aff>University of Illinois</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Uzma Ismail declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Killeen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148512.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Taxanes are widely-used chemotherapy agents for treating various solid malignancies and work as microtubule inhibitors. The resulting cell cycle inhibition during the G2/M phase activates the cellular apoptosis pathways. They form the backbone of chemotherapeutic regimens in breast, ovarian, non-small cell lung, and head and neck cancers. Extensive toxicities, including hypersensitivity reactions, myelosuppression, and neuropathy, often limit the use of taxanes. This activity reviews the etiology, incidence, evaluation, and treatment of different adverse events related to taxanes. It highlights the importance of the interprofessional team and patient education for promptly managing this problem.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of taxane toxicity.</p></list-item><list-item><p>Describe the common adverse effects of different taxanes.</p></list-item><list-item><p>Outline the treatment of various adverse effects of taxane therapy.</p></list-item><list-item><p>Review the importance of patient education and interprofessional team for the early detection of taxane toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148512&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148512">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148512.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Taxanes are a diverse class of chemotherapeutic agents comprising paclitaxel, docetaxel, cabazitaxel, and albumin-bound paclitaxel (nab-paclitaxel), which work&#x000a0;by stabilization of the microtubules. The resulting cell cycle inhibition during the G2/M phase activates the cellular apoptosis pathways.<xref ref-type="bibr" rid="article-148512.r1">[1]</xref>&#x000a0;</p>
        <p>Paclitaxel was the first drug from this class that got FDA approval in 1992 for treating ovarian cancer after failure of first-line or&#x000a0;later therapy. Subsequently, it was approved for metastatic breast cancer, AIDS-related Kaposi sarcoma, non-small cell lung carcinoma, and bladder cancer. FDA first approved docetaxel in 1996 for the treatment of metastatic breast cancer. Currently, it is approved for use in non-small cell lung cancer, head and neck cancer, gastric cancer, prostate cancer, and ovarian cancer. Cabazitaxel is being extensively prescribed for docetaxel-resistant metastatic castration-resistant prostate cancer. Nab-paclitaxel&#x000a0;is used in the treatment of advanced pancreatic cancer, breast cancer, and non-small cell lung cancer.<xref ref-type="bibr" rid="article-148512.r2">[2]</xref></p>
        <p>Despite forming the chemotherapy backbone of various malignancies, the use of taxanes is hindered by their side effects profile. Often the side effects are increased when these drugs are prescribed in combination with other&#x000a0;medicines like platinum agents and doxorubicin. The side effects vary between different taxanes, but&#x000a0;the common&#x000a0;ones include myelosuppression, neuropathy, and hypersensitivity reactions.<xref ref-type="bibr" rid="article-148512.r3">[3]</xref>&#x000a0;</p>
        <p>Taxanes have been known to cause (upper) gastrointestinal bleeding.<xref ref-type="bibr" rid="article-148512.r4">[4]</xref>&#x000a0;The unique toxicities of paclitaxel include cardiac conduction abnormalities, specifically bradycardia, alopecia, nail discoloration, and rarely hepatitis and pneumonitis. Docetaxel leads to&#x000a0;characteristic fluid retention, skin toxicities, and stomatitis. Cabazitaxel toxicities consist of infections, nausea, vomiting, diarrhea, and constipation.<xref ref-type="bibr" rid="article-148512.r5">[5]</xref> Nab-paclitaxel is characterized by a lack of&#x000a0;hypersensitivity reactions but can cause nausea and vomiting, alopecia, arthralgia, myalgia, and elevation of liver enzymes.<xref ref-type="bibr" rid="article-148512.r6">[6]</xref></p>
      </sec>
      <sec id="article-148512.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Taxane toxicity is common primarily because the drugs are extensively prescribed in oncology and have peculiar molecular structures. Paclitaxel was first separated from the bark of the tree<italic toggle="yes"> Taxus brevifolia,&#x000a0;</italic>although presently, synthetic and semi-synthetic forms of the compounds are increasingly used. Similarly, the motivation to identify further taxanes led to the discovery of docetaxel from the needles of the abundantly available tree <italic toggle="yes">Taxus baccata.</italic></p>
        <p>The effective delivery and distribution of paclitaxel and docetaxel require the support of solvents which include chromophore-ethanol and polysorbate 80, respectively. Natural sources and solvents are mainly responsible for infusion-related hypersensitivity reactions. Recent evidence has suggested that some of these reactions might be IgE-mediated.<xref ref-type="bibr" rid="article-148512.r7">[7]</xref>&#x000a0;</p>
        <p>Nab-paclitaxel is the nano-particle formulation of paclitaxel which is bound to the albumin during travel through the blood and therefore doesn't cause hypersensitivity during infusion.<xref ref-type="bibr" rid="article-148512.r8">[8]</xref> Cabazitaxel was developed to overcome the resistance faced by paclitaxel and docetaxel. Its structure is similar to docetaxel, and thus the risk of hypersensitivity reactions is the same.<xref ref-type="bibr" rid="article-148512.r5">[5]</xref></p>
        <p>Paclitaxel has the principal toxicity of neuropathy which presents in gloves and stocking distribution and can become permanent if left untreated. The neuropathy pattern is usually sensory and occurs due to axonal degeneration and demyelination. Neutropenia and mucositis are other side effects of paclitaxel which are dependent on the duration of exposure to the drug.<xref ref-type="bibr" rid="article-148512.r9">[9]</xref> Cardiac disturbances, especially bradycardia, have been noted during paclitaxel infusion, but these are usually benign, and no cause has been identified.<xref ref-type="bibr" rid="article-148512.r10">[10]</xref></p>
        <p>Docetaxel has a unique toxicity of fluid retention. It is cumulative and is believed to be due to increased capillary permeability. Neutropenia is docetaxel's dose-limiting toxicity, which is more common with 3-weekly regimens.&#x000a0;The neuropathy is less severe with docetaxel than with paclitaxel, likely due to structural differences.<xref ref-type="bibr" rid="article-148512.r11">[11]</xref></p>
        <p>Nab-paclitaxel is extensively distributed in the plasma due to its unique combination with albumin. The volume of distribution and bioavailability is thus higher than paclitaxel. This results in improved drug efficacy at the cost of more prevalence of neutropenia and sensory neuropathy.<xref ref-type="bibr" rid="article-148512.r12">[12]</xref></p>
      </sec>
      <sec id="article-148512.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Initially, hypersensitivity reactions were noticed in 30% of patients who received paclitaxel and docetaxel; however, the use of premedication has decreased the incidence to 1 to 2%. Typically, these occur within the first 10 minutes during the first or second infusion, and the incidence is negligible afterward.<xref ref-type="bibr" rid="article-148512.r7">[7]</xref></p>
        <p>The incidence of bradycardia with paclitaxel is about 30%, while 30 to 40% of patients experience mucositis. Skin rash and onycholysis are relatively less common and occur in 5 to 10% of patients.<xref ref-type="bibr" rid="article-148512.r13">[13]</xref></p>
        <p>Docetaxel results in characteristic skin toxicity in about 80% of patients.<xref ref-type="bibr" rid="article-148512.r14">[14]</xref></p>
        <p>The incidence of haematologic toxicity is very high, with cabazitaxel with neutropenia being observed in greater than 90% of patients.<xref ref-type="bibr" rid="article-148512.r5">[5]</xref></p>
      </sec>
      <sec id="article-148512.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Hypersensitivity reactions are experienced immediately after starting the drug. Minor reactions are observed in 40% of cases and cause urticaria or skin rash. Significant reactions&#x000a0;comprise nausea, vomiting, flushing, urticaria, shortness of breath, wheezing, tachycardia, hypotension, and abdominal or chest pain.<xref ref-type="bibr" rid="article-148512.r7">[7]</xref></p>
        <p>Neuropathy presents as a tingling sensation in hands and feet with numbness. Rarely, the patient may also complain of motor weakness and urinary or fecal incontinence. Examination typically reveals sensory loss in gloves and stocking distribution. Motor and autonomic examinations are often unremarkable.<xref ref-type="bibr" rid="article-148512.r15">[15]</xref></p>
        <p>Mucositis can be caused by all the taxanes and is characterized by oral ulcers, nausea, vomiting, and diarrhea.</p>
        <p>Docetaxel-induced fluid retention is often characterized by pedal and ankle edema, weight gain, abdominal distension, shortness of breath, and facial swelling.<xref ref-type="bibr" rid="article-148512.r16">[16]</xref></p>
        <p>Skin toxicity is a common side effect of docetaxel.&#x000a0;Most patients experience mild dermatitis, nail discoloration, and alopecia; however, the severe spectrum of&#x000a0;toxicity results in&#x000a0;hand and foot desquamation, onycholysis, and erythroderma.<xref ref-type="bibr" rid="article-148512.r16">[16]</xref></p>
        <p>Cardiac abnormalities with paclitaxel are benign, and bradycardia is the most common incidental finding.<xref ref-type="bibr" rid="article-148512.r13">[13]</xref></p>
        <p>Ophthalmic toxicity, though uncommon (1 to 2%), could come in many forms, including meibomian gland dysfunction, cystoid macular edema, and canalicular obstruction.<xref ref-type="bibr" rid="article-148512.r17">[17]</xref>&#x000a0;These toxicities can be addressed without discontinuing therapy.</p>
      </sec>
      <sec id="article-148512.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Complete blood count and liver function tests are typically prescribed with 3-weekly infusions to detect neutropenia, thrombocytopenia, and elevation of liver transaminases. There are no proven guidelines for routine blood tests in weekly drug regimens, and institutional policies should be followed.&#x000a0;</p>
        <p>Recent studies have noted a genetic predisposition to taxane toxicity.<xref ref-type="bibr" rid="article-148512.r18">[18]</xref>&#x000a0;Cytochrome P450 (CYP3A4 and CYP3A5) metabolizes docetaxel into inactive compounds that are cleared from the body. Though rare (0.2% homozygous), some variants have reduced or less-of-function. This causes compound retention and augments its toxicity. Other medications reportedly do not worsen the situation, but other genetic anomalies (e.g., SLCO1B3, ABCC2, ABCB1) are thought to compound the problem.&#x000a0;</p>
        <p>Taxane skin testing is an effective method to identify IgE-mediated hypersensitivity reactions.<xref ref-type="bibr" rid="article-148512.r7">[7]</xref></p>
        <p>The suspicion of neutropenic enterocolitis can be confirmed through ultrasonography abdomen to evaluate the gut thickness.</p>
        <p>The investigation of neuropathy includes nerve conduction studies to confirm axonal damage.</p>
      </sec>
      <sec id="article-148512.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The majority of toxicities associated with taxanes are reversible with appropriate and timely management. Both prophylactic measures and treatment modalities help counter adverse events.</p>
        <p>Hypersensitivity reactions can be prevented by using prophylactic steroids and premedication. The typical docetaxel regimens include 3-weekly infusions, and prophylactic steroids are recommended for 72 hours, starting 24 hours before the drug administration. The dose of dexamethasone is 8mg bid.&#x000a0;Cabazitaxel is used as a single agent given every three weeks. The dose of dexamethasone is 10mg daily through all the cycles of cabazitaxel.<xref ref-type="bibr" rid="article-148512.r19">[19]</xref>&#x000a0;</p>
        <p>In the case of paclitaxel, dexamethasone is given 20mg, 12 and 6 hours before drug administration. Apart from steroids, the premedication is given 30 minutes before starting the taxane infusion and usually includes diphenhydramine 50mg IV and cimetidine 300mg IV or any other H2-blockers. Nab-paclitaxel is the only taxane that doesn't require routine use of prophylactic steroids or premedication.</p>
        <p>If&#x000a0;a major hypersensitivity reaction occurs despite premedication, immediately stop the infusion and give high-dose steroids. The minor reactions don't need any medication. Life-threatening anaphylactic reactions may require adrenaline. Symptoms usually resolve within 15 minutes. Taxane skin testing and the severity of hypersensitivity reaction dictate the re-introduction of the drug, which could include rapid&#x000a0;drug desensitization or graded exposure. Rapid desensitization is safe and effective with premedication given 30 minutes before rechallenge.<xref ref-type="bibr" rid="article-148512.r20">[20]</xref>&#x000a0;Patients with severe reactions to paclitaxel are at increased risk of similar reactions to docetaxel.&#x000a0;Nab-paclitaxel can be prescribed in such situations.</p>
        <p>Taxane-induced neurotoxicity can be challenging to treat. There&#x000a0;is no convincing evidence that any antidotes&#x000a0;are effective at ameliorating the existing complaints or helping prevent the onset of neuropathy.&#x000a0;Neuropathic pain is less responsive to conventional non-opioid and opioid analgesics. The preferred management of painful neuropathy revolves around antidepressants. Tricyclic antidepressants (TCAs) have been used historically preferred in this context.</p>
        <p>Agents like amitriptyline, doxepin, imipramine, and nortriptyline have analgesic effects, and the dose required for pain relief is much less than the one used for depression.<xref ref-type="bibr" rid="article-148512.r21">[21]</xref>&#x000a0;However, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are increasingly being used for chemotherapy-related neurotoxicity. Duloxetine belongs to the SNRIs group&#x000a0;and has proven efficacy in relieving diabetic neuropathy.<xref ref-type="bibr" rid="article-148512.r22">[22]</xref></p>
        <p>Clinically, it has been the preferred agent to treat taxane neuropathy, particularly the painful disease.<xref ref-type="bibr" rid="article-148512.r23">[23]</xref>&#x000a0;Anticonvulsants like gabapentin and pregabalin reduce the pain intensity in noncancer neuropathy.<xref ref-type="bibr" rid="article-148512.r22">[22]</xref>&#x000a0;However, a recent systematic review failed to demonstrate conclusive evidence of the benefit of pregabalin in cancer patients.<xref ref-type="bibr" rid="article-148512.r24">[24]</xref> Local anesthetics and corticosteroids&#x000a0;can be co-administrated with other drugs to relieve neuropathic pain.<xref ref-type="bibr" rid="article-148512.r25">[25]</xref>&#x000a0;</p>
        <p>Hilotherapy has had some success in treating Taxane-peripheral neuropathy.<xref ref-type="bibr" rid="article-148512.r26">[26]</xref>&#x000a0;This modality involves thermally-generated water cuffs that provide a constant temperature over an affected limb, hand, or feet.&#x000a0;</p>
        <p>Neutropenia is the main dose-limiting toxicity of docetaxel, while it is also frequently seen with paclitaxel. Docetaxel should not be given if the absolute neutrophil count is less than 1500/mm3.<xref ref-type="bibr" rid="article-148512.r11">[11]</xref> The severity of neutropenia has been established through clinical trials for the vast majority of chemotherapy agents. The expected risk of neutropenia above 20% warrants the prophylactic use of granulocyte colony-stimulating growth factors (G-CSF).<xref ref-type="bibr" rid="article-148512.r27">[27]</xref>&#x000a0;</p>
        <p>Docetaxel-containing regimens given every three weeks fall into this high-risk category and require routine G-CSF prescription. If patients have ANC of &#x0003c;1500/mm^3 despite G-CSF and no active complaints, it's best to delay the therapy. Patients with low ANC and fever should be managed as neutropenic sepsis on an outdoor or indoor basis, according to the MASCC score.<xref ref-type="bibr" rid="article-148512.r28">[28]</xref></p>
        <p>The chief purpose of steroids prophylaxis in docetaxel is the prevention of fluid retention rather than hypersensitivity reactions, although it helps with both. Severe ascites or pleural effusion can be treated with diuretics like furosemide, and fluid paracentesis is rarely needed.<xref ref-type="bibr" rid="article-148512.r16">[16]</xref>&#x000a0;Dexamethasone use also prevents skin toxicity which is the major problem with docetaxel. Treatment of established skin rash includes topical steroids, emollients, vitamin A, and dermatology opinion.<xref ref-type="bibr" rid="article-148512.r29">[29]</xref></p>
        <p>The paclitaxel-associated bradycardia is an incidental finding that doesn't require cardiac monitoring during therapy. Often, no active management or cardiologist opinion is needed.&#x000a0;</p>
        <p>Taxane-induced arthralgias and myalgias have been found to have a possible ideal treatment with flupirtine.<xref ref-type="bibr" rid="article-148512.r30">[30]</xref>&#x000a0;One study noted above 93% incidence of arthralgia/myalgia, but there was an improvement with the administration of this analgesic. It provides analgesia through the blockade of glutamate-N-methyl-D-aspartate receptors.<xref ref-type="bibr" rid="article-148512.r31">[31]</xref>&#x000a0;It is non-opioid with few side effects.</p>
      </sec>
      <sec id="article-148512.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Hypersensitivity&#x000a0;Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic sinusitis</p>
          </list-item>
          <list-item>
            <p>Urticaria</p>
          </list-item>
          <list-item>
            <p>Angioedema</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis to dietary or environmental factors</p>
          </list-item>
          <list-item>
            <p>Anxiety disorder</p>
          </list-item>
          <list-item>
            <p>Pulmonary embolism</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction</p>
          </list-item>
        </list>
        <p>
<bold>Neuropathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcoholism</p>
          </list-item>
          <list-item>
            <p>Diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Pernicious anemia</p>
          </list-item>
          <list-item>
            <p>Dietary deficiencies</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Lyme disease</p>
          </list-item>
          <list-item>
            <p>HIV</p>
          </list-item>
        </list>
        <p>
<bold>Fluid Retention</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypoalbuminemia</p>
          </list-item>
          <list-item>
            <p>Congestive cardiac failure</p>
          </list-item>
          <list-item>
            <p>Chronic liver failure</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-148512.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Although the rate of taxane-induced adverse events is high, there is often full recovery, except for neuropathy. Patients with diabetes or a history of alcohol abuse are more prone to develop persistent neurotoxicity. Early and prompt management of both neuropathy and comorbidities often avoids long-term disability.&#x000a0;&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-148512.s10" sec-type="Complications">
        <title>Complications</title>
        <p>The irreversible complications of taxane therapy are rare. The combination of doxorubicin and paclitaxel is associated with a higher risk of congestive cardiac failure, which could be persistent. Similarly, there are reports of scleroderma-like cutaneous syndrome with taxanes, particularly docetaxel.<xref ref-type="bibr" rid="article-148512.r14">[14]</xref>&#x000a0;</p>
        <p>The rare sequelae of long-term therapy could also lead to pneumonitis. A recent study noted that, save for neutropenia, Taxane toxicity was generally manageable with premedications, monitoring, and close reactive care.<xref ref-type="bibr" rid="article-148512.r32">[32]</xref>&#x000a0;</p>
        <p>Discontinuing a chemotherapy agent with significant potential benefit to the patient over an "event" was generally viewed with disdain.</p>
      </sec>
      <sec id="article-148512.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>It is crucial to explain the possible toxicities associated with the taxanes to the patients. They should be educated about the lifestyle measures like regular sunscreen application and sun avoidance to avoid paclitaxel-induced dermatitis. Patients should be aware of the signs and symptoms of neutropenic fever so they may seek urgent help. The chemotherapy nurse and pharmacist are essential in educating the patients and their families. Exercise can help improve neuropathy, so physiotherapists can help plan a regular exercise program.</p>
      </sec>
      <sec id="article-148512.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In general, an interprofessional team consisting of clinicians, nurses, and pharmacists, is mandatory for an integrated approach to identify and manage drug toxicities. The role of specialist staff nurses to educate patients can not be emphasized enough, and coordinating dosing, administration, and monitoring with the pharmacists is prudent if there is any ambiguity. All the patients should be fully counseled regarding symptoms of taxane toxicity through audio and visual tools so they may seek early help. The earlier the signs and symptoms of a complication are detected, the better the prognosis and quality of life. This is where the interprofessional approach can derive maximum patient benefit. [Level 5]</p>
      </sec>
      <sec id="article-148512.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148512&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148512">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/taxane-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=148512">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148512/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148512">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148512.s14">
        <title>References</title>
        <ref id="article-148512.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mosca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ilari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fazi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Assaraf</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Colotti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.</article-title>
            <source>Drug Resist Updat</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>54</volume>
            <fpage>100742</fpage>
            <pub-id pub-id-type="pmid">33429249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christensen</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides.</article-title>
            <source>Molecules</source>
            <year>2022</year>
            <month>Sep</month>
            <day>01</day>
            <volume>27</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">36080414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lao</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JZ</given-names>
              </name>
            </person-group>
            <article-title>Assessing taxane-associated adverse events using the FDA adverse event reporting system database.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>134</volume>
            <issue>12</issue>
            <fpage>1471</fpage>
            <page-range>1471-1476</page-range>
            <pub-id pub-id-type="pmid">34074841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hiramoto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tatishchev</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Taxane-Induced Upper Gastrointestinal Bleeding.</article-title>
            <source>Case Rep Oncol</source>
            <year>2021</year>
            <season>Sep-Dec</season>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>1373</fpage>
            <page-range>1373-1379</page-range>
            <pub-id pub-id-type="pmid">34720944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meisel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>von Felten</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Liewen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Bono</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sartor</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Stenner-Liewen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.</article-title>
            <source>Eur J Cancer</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>56</volume>
            <fpage>93</fpage>
            <page-range>93-100</page-range>
            <pub-id pub-id-type="pmid">26829012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muggia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kudlowitz</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Novel taxanes.</article-title>
            <source>Anticancer Drugs</source>
            <year>2014</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>593</fpage>
            <page-range>593-8</page-range>
            <pub-id pub-id-type="pmid">24374330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Picard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castells</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-91</page-range>
            <pub-id pub-id-type="pmid">24740483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallego-Jara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lozano-Terol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sola-Mart&#x000ed;nez</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>C&#x000e1;novas-D&#x000ed;az</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Diego Puente</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A Compressive Review about Taxol<sup>&#x000ae;</sup>: History and Future Challenges.</article-title>
            <source>Molecules</source>
            <year>2020</year>
            <month>Dec</month>
            <day>17</day>
            <volume>25</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">33348838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EML</given-names>
              </name>
              <name>
                <surname>Stringer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>194</volume>
            <issue>3</issue>
            <fpage>551</fpage>
            <page-range>551-560</page-range>
            <pub-id pub-id-type="pmid">35760975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zekri</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Case report and review of literature: temporary asymptomatic sinus bradycardia with carboplatin, paclitaxel and bevacizumab: under-reported in clinical trials and under-disclosed in practice.</article-title>
            <source>Gulf J Oncolog</source>
            <year>2011</year>
            <month>Jul</month>
            <issue>10</issue>
            <fpage>60</fpage>
            <page-range>60-4</page-range>
            <pub-id pub-id-type="pmid">21724531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial.</article-title>
            <source>Technol Cancer Res Treat</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>21</volume>
            <fpage>15330338221109974</fpage>
            <pub-id pub-id-type="pmid">35770295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mumper</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>A critical review of lipid-based nanoparticles for taxane delivery.</article-title>
            <source>Cancer Lett</source>
            <year>2013</year>
            <month>Jul</month>
            <day>01</day>
            <volume>334</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-75</page-range>
            <pub-id pub-id-type="pmid">22796606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schrader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keussen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bewig</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>von Freier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lins</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma.</article-title>
            <source>Eur J Med Res</source>
            <year>2005</year>
            <month>Nov</month>
            <day>16</day>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>498</fpage>
            <page-range>498-501</page-range>
            <pub-id pub-id-type="pmid">16354605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marks</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events: A Systematic Review.</article-title>
            <source>JAMA Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>154</volume>
            <issue>12</issue>
            <fpage>1465</fpage>
            <page-range>1465-1472</page-range>
            <pub-id pub-id-type="pmid">30383138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catalano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aprile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petrioli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roviello</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer.</article-title>
            <source>Oncology</source>
            <year>2022</year>
            <volume>100</volume>
            <issue>7</issue>
            <fpage>384</fpage>
            <page-range>384-391</page-range>
            <pub-id pub-id-type="pmid">35551139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Semb</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Aamdal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oian</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.</article-title>
            <source>J Clin Oncol</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>3426</fpage>
            <page-range>3426-32</page-range>
            <pub-id pub-id-type="pmid">9779722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fortes</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dalvin</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Ophthalmic adverse effects of taxanes: The Mayo Clinic experience.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>602</fpage>
            <page-range>602-611</page-range>
            <pub-id pub-id-type="pmid">33148049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Shugg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Albany</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Radovich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Skaar</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>809527</fpage>
            <pub-id pub-id-type="pmid">35174070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarantopoulos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mita</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hsueh</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clot</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Rixe</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>339</fpage>
            <page-range>339-351</page-range>
            <pub-id pub-id-type="pmid">28058445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Picard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pur</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Caiado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giavina-Bianchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Galv&#x000e3;o</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Matulonis</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Castells</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>137</volume>
            <issue>4</issue>
            <fpage>1154</fpage>
            <page-range>1154-1164.e12</page-range>
            <pub-id pub-id-type="pmid">26725998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McQuay</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Sindrup</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Algorithm for neuropathic pain treatment: an evidence based proposal.</article-title>
            <source>Pain</source>
            <year>2005</year>
            <month>Dec</month>
            <day>05</day>
            <volume>118</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-305</page-range>
            <pub-id pub-id-type="pmid">16213659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Detke</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Iyengar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Duloxetine vs. placebo in patients with painful diabetic neuropathy.</article-title>
            <source>Pain</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>116</volume>
            <issue>1-2</issue>
            <fpage>109</fpage>
            <page-range>109-18</page-range>
            <pub-id pub-id-type="pmid">15927394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cirrincione</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fleishman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paskett</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Ahles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fadul</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le-Lindqwister</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gilman</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>CL</given-names>
              </name>
              <collab>Alliance for Clinical Trials in Oncology</collab>
            </person-group>
            <article-title>Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Apr</month>
            <day>03</day>
            <volume>309</volume>
            <issue>13</issue>
            <fpage>1359</fpage>
            <page-range>1359-67</page-range>
            <pub-id pub-id-type="pmid">23549581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Laird</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Litsenburg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nimour</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature.</article-title>
            <source>Pain Med</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>1681</fpage>
            <page-range>1681-8</page-range>
            <pub-id pub-id-type="pmid">23915361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanos</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Galluzzi</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Topical therapies in the management of chronic pain.</article-title>
            <source>Postgrad Med</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>125</volume>
            <issue>4 Suppl 1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">24547601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coolbrandt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vancoille</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dejaeger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laenen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Punie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wildiers</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>192</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-301</page-range>
            <pub-id pub-id-type="pmid">34982322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashariati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bintoro</surname>
                <given-names>UY</given-names>
              </name>
              <name>
                <surname>Savitri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diansyah</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Amrita</surname>
                <given-names>PNA</given-names>
              </name>
              <name>
                <surname>Romadhon</surname>
                <given-names>PZ</given-names>
              </name>
              <name>
                <surname>Wijaya</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Hendrata</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Looi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mahmudin</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.</article-title>
            <source>Acta Med Indones</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <page-range>371-378</page-range>
            <pub-id pub-id-type="pmid">36156473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of toxicities associated with the administration of taxanes.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-6</page-range>
            <pub-id pub-id-type="pmid">12904114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sibaud</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leb&#x00153;uf</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Belum</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Gladieff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deslandres</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montastruc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eche</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vigarios</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dalenc</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Dermatological adverse events with taxane chemotherapy.</article-title>
            <source>Eur J Dermatol</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>427</fpage>
            <page-range>427-443</page-range>
            <pub-id pub-id-type="pmid">27550571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Razak</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Binoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devi</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Pavithran</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Flupirtine in the Management of Taxane-induced Pain in Cancer Patients.</article-title>
            <source>Indian J Palliat Care</source>
            <year>2022</year>
            <season>Jul-Sep</season>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>262</fpage>
            <page-range>262-265</page-range>
            <pub-id pub-id-type="pmid">36072241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harish</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhuvana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bengalorkar</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Flupirtine: Clinical pharmacology.</article-title>
            <source>J Anaesthesiol Clin Pharmacol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-7</page-range>
            <pub-id pub-id-type="pmid">22557738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148512.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>A systemic review of taxanes and their side effects in metastatic breast cancer.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>940239</fpage>
            <pub-id pub-id-type="pmid">36303832</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
